Welcome to our dedicated page for Avalon GloboCare news (Ticker: ALBT), a resource for investors and traders seeking the latest updates and insights on Avalon GloboCare stock.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a pioneering biotech company specializing in precision diagnostics, clinical laboratory services, and transformative biotechnology. The company operates through two primary segments: the real property operating segment, which drives its revenue, and the medical-related consulting services segment. As an innovative healthcare service provider, Avalon focuses on key diagnostic and therapeutic areas such as early detection of oral, ovarian, and kidney cancers, as well as skin regeneration and treatments for degenerative disorders.
Headquartered in Freehold, NJ, Avalon is committed to advancing high-impact biotechnology and clinical applications. Recently, the company launched Veritas Laboratory in Scottsdale, Arizona, a CLIA-certified and COLA-accredited facility offering comprehensive drug, genetic, urinary, and COVID-19 PCR testing. Moreover, Avalon continuously expands its testing footprint nationwide, leveraging the expertise of former Congressman Barry M. Goldwater Jr. to enhance insurance coverage and laboratory reach.
The company has introduced groundbreaking innovations such as the proprietary TB detection method and the KetoAir™ breathalyzer. The TB test, developed by Laboratory Services MSO, LLC (LSM), uses PCR technology for rapid and accurate tuberculosis detection from sputum samples. The KetoAir™ breathalyzer, a partnership with Qi Diagnostics, offers AI-driven nutritional insights for ketogenic dietary management.
Avalon’s strategic acquisitions underscore its growth trajectory. The acquisition of Merlin Medical Supply (MMS) and Leading Edge Innovations enhances its portfolio with durable medical equipment and the GeeWhiz External Condom Catheter, bolstering its presence in the medical supply market.
Further strengthening its intellectual property, Avalon recently secured a patent for QTY-Code modified cytokine and chemokine protein receptors, expanding the therapeutic targets for diseases like cancer. The company continues to innovate with upcoming studies on the DKAir™ breathalyzer for early detection of diabetic ketoacidosis.
For detailed information about Avalon GloboCare’s projects, recent developments, and strategic initiatives, visit their website and follow them on Twitter at @avalongc_avco.
Avalon GloboCare (NASDAQ: ALBT) has launched the 'BrAce for Impact' affiliate marketing program for KetoAir™, an AI-enabled breathalyzer device for ketogenic health monitoring. The program, developed following demand from recent health conferences, offers affiliates discount codes and commissions on sales.
The initiative provides marketing materials and brand resources to affiliates, targeting metabolic coaches, podcasters, health authors, and influencers. KetoAir™, FDA-registered (No. 3026284320), measures breath acetone concentration using nano-sensor technology to assess ketosis status, with companion apps available on both Apple and Google platforms.
Avalon GloboCare (NASDAQ: ALBT) has appointed Dr. Charles Cavo to its Scientific and Clinical Advisory Board to support the development of KetoAir™, a handheld breathalyzer for ketogenic health monitoring. Dr. Cavo, co-founder and CMO of Pounds Transformation, brings expertise in obesity medicine and bariatric care. KetoAir™ measures Breath Acetone Concentration (BrAce) as a biomarker for ketosis, offering a non-invasive alternative to blood and urine testing. The device aims to support weight management and conditions like diabetes by providing real-time feedback on ketosis levels.
Avalon GloboCare (NASDAQ: ALBT) has entered into a memorandum of understanding with Qi Diagnostics to explore co-developing a VOC nanosensor-based cannabis breathalyzer. The MOU grants Avalon a 120-day exclusivity period to negotiate a definitive agreement. If successful, the collaboration would focus on developing a prototype for detecting cannabis, leveraging Avalon's regulatory expertise and experience with clinical trials. The project aims to address point-of-care testing needs in law enforcement and workplace safety. However, there is no guarantee that a definitive agreement will be reached during the exclusivity period.
Avalon GloboCare (NASDAQ: ALBT) has announced a 1-for-15 reverse stock split effective October 28, 2024, as part of its strategy to regain compliance with Nasdaq's $1.00 minimum bid price requirement. The reverse split will reduce outstanding common shares from approximately 16.0 million to 1.1 million. The company will continue trading under the symbol 'ALBT' with a new CUSIP number 05344R302. The move is aimed at maintaining Nasdaq listing while the company continues focusing on its precision diagnostics and laboratory services business.
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced its sponsorship of the Keto Pa-LOU-za 2024 Conference, taking place October 11-13, 2024, in Louisville, KY. The company will showcase its KetoAir™ breathalyzer device, designed to monitor ketosis through breath analysis. Conference attendees will have the opportunity to see live demonstrations and purchase the device along with related accessories on-site.
The KetoAir™ breathalyzer is a handheld device specifically engineered for ketogenic health management. It measures breath acetone concentration (BrAce) to assess ketosis status without invasive blood tests. The device is FDA-registered and accessible via both Apple App Store and Google Play Store. Avalon's subsidiary, Q&A Distribution , holds exclusive distributorship rights for KetoAir™ in North America, South America, EU, and UK.
Avalon GloboCare Corp. (NASDAQ: ALBT) announced that Laboratory Services MSO, (LSM), in which Avalon owns a 40% stake, will begin manufacturing and selling the GeeWhiz External Condom Catheter, an FDA-registered male incontinence device. The product launch is planned for Q3 2024. The device is approved for Medicare reimbursement and supported by several private insurers.
The global male urinary incontinence market, valued at $6.37 billion in 2022, is projected to grow at a CAGR of 5.87% from 2023 to 2030. This growth is driven by increasing incontinence prevalence, an aging population, and technological advancements. The GeeWhiz catheter aims to provide enhanced comfort, security, and ease of use for men with urinary incontinence and bladder control issues.
Avalon GloboCare Corp. (NASDAQ: ALBT) has announced the launch of a direct-to-consumer DNA test for opioid addiction predisposition through its 40% owned Laboratory Services MSO. The DNA4Addiction test analyzes 15 genetic markers linked to opioid dependence, categorizing individuals into risk levels. This non-invasive, at-home test comes amid the ongoing opioid crisis, with opioids involved in over 75% of nearly 107,000 drug overdose deaths in 2022.
The test aims to provide insights for proactive health management, though it is not a diagnosis. It examines factors such as neurotransmitter activity and substance sensitivity. Dr. David Jin, CEO of Avalon, emphasized the importance of recognizing genetic predisposition for early intervention. Bob Forrest, Brand Ambassador for DNA4Addiction, highlighted its potential in guiding lifestyle changes and preventing addiction, especially for parents concerned about their children's risks.
Avalon GloboCare Corp. (NASDAQ: ALBT) has launched online sales of the KetoAir™ breathalyzer in the U.S. at www.ketoair.us. This FDA-registered device features Hot App shareable technology with AI-enabled software for ketogenic health management. The KetoAir™ breathalyzer uses nano-sensor-based technology and AI algorithms to assess ketosis status and record diet and exercise details via its app.
The device offers personalized nutritional and exercise recommendations through its AI nutritionist feature. Avalon has exclusive distributorship rights for KetoAir™ in North America, South America, EU, and the UK. To celebrate the launch, Avalon is offering a special introductory price of $199 (regular $249) with an additional 20% discount using coupon code 'intro20'.
Avalon GloboCare announced the successful U.S. launch of its KetoAir™ breathalyzer at the Hack Your Health by KetoCon 2024 Conference. The event, held from May 31 to June 2, 2024, in Austin, Texas, attracted diverse stakeholders such as doctors, health coaches, and retailers. The device, registered with the FDA (No. 3026284320), uses AI-enabled software and nano-sensor technology to monitor ketosis through a non-invasive breath test. Avalon introduced a Zero to Keto program and expects retail sales to begin later this month, with purchases available exclusively at KetoAir.com.
Avalon GloboCare (NASDAQ: ALBT) announced that it has received a notice from Nasdaq on May 22, 2024, stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) due to its failure to file the Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024.
The notice does not affect the immediate listing or trading of Avalon's common stock. The company has until July 22, 2024, to submit a plan to regain compliance. If accepted, Nasdaq may allow until November 18, 2024, for Avalon to file the report and regain compliance. Avalon is working to finalize and file the report promptly.
FAQ
What is the current stock price of Avalon GloboCare (ALBT)?
What is the market cap of Avalon GloboCare (ALBT)?
What does Avalon GloboCare Corp. do?
What are the core segments of Avalon GloboCare's business?
What recent acquisitions has Avalon GloboCare made?
What is the KetoAir™ breathalyzer?
What innovations has Avalon introduced in TB testing?
Who is Barry M. Goldwater Jr. and how is he related to Avalon?
What is Avalon’s QTY-Code modified protein receptor patent?
What is the DKAir™ breathalyzer?
How is Avalon addressing the medical supply market?
How can I stay updated on Avalon GloboCare's developments?
